23.06.02 () 05:10

Dailypharm

X
ı ҿ ,
ϸ 2017-05-13 06:14:50
/home/dailypharm/issueData2017/
ʸƮ
ı ҿ ,
ϸ 2017-05-13 06:14:50
ü , 漼



[2] 漼

츮 ȸ dz ԰Ÿ ̵ ڵȭ ο ÿ ̻ ü ׻ ׿ 缺 ȯ ϵ ġ ȯ ߺ μӿ ִ. ̿ Ȳ ذ コɾ ־ ߿ ٽɰ ϳ ƴ.

׷ Ϸ绡 񸸿 Żϰ ϴ п پϰ ǰ ִ ȫӿ δ κ ü ִ. ȯ ɰϴ. ü ع 翬 ԰ ̴ ̴. ׷ ׷ µ鿡 ο ϰ ư ʱ⿡ ãƾ ʿ䰡 ִ. ̷ 翬ϸ鼭 ġ ȭ ̷ϴ ü Ư¡̴. ܼ ſ ƴϴ. ü Ư¡ ϱ? ׸  ؾ ϴ°ϱ?

4 Queensland University of Technology Institute of Health and Biomedical Innovation Faculty of Science and Engineering Saba Farnaghi ڻ ROLE OF HYPERCHOLESTEROLEMIA IN OSTEOARTHRITIS DEVELOPMENT ſ ǹִ ߴ. ұϰ ü߿ ̻ ı ȯ ΰ ִ ɸ Ǵ ϴ . , ༺ (, OA) ߺ ̻ ģ 뿡 θ ̴. ڴ apolipoprotein E- (ApoE−/−) ̿ ݷ׷ ߽Ų 𵨿 proteoglycans collagen ս, aggrecan( ϴ ֿ chondroitin sulfate ϴ proteoglycan) ı, Ȱ׸ , () , ϰ ȭ , ׸ ᱹ ı ̻ ͰǴ Ұߵ ߴ. ݿ Ŀ 麸 ̵ 豺(̻, ) 鿡 ȭƴ. , ° ܵ帮 , Ȱ ׻ ıϴ Ŀ ڷμ ߱ ̴. ̴ atorvastatin ܵ帮Ƹ Ȱ κ ȣϴ mitochondria targeted anti-oxidants (mito-TEMPO, MitoQ) ȭ Ʈ ȸ ̻ ϴ ȭ ߴ. ׷ ڴ ̻(ݷ׷) 缺 ڵ ܵ帮ƿ ȭ Ʈ ۿ ȭ״ٸ鼭 ġῡ ־ Ǵ Ȱ ġᰡ ߿ϴٰ ߴ.

׷ٸ Ȯϰ  ı ҵ  Ŀ ̷ 2 ȯ ߺ Ǵ ȭŲ ϱ?

Ҹ ұ ʷϴ ü ū Ư¡̸ 漼 (adipogenesis) Ǵ ̷. Adipogenesis 漼ü(pre-adipocyte) 漼(adipocyte) ȭ(differentiation) ܰ ġµ, ̶ ٽ ϴ peroxisome proliferator activated receptor (PPAR)̴. PPAR Ȱ ( տ ȰȭǾ 縦 ϴ , ligand activated trascription factor family) ϸ Ǵ 濡 ̳ ȴ. ̴ 漼ü(Ǵ Ƽ) 漼 ȭǴµ ʿ 漼 ռ 忡 䱸Ǵ ܹ Ǵ ڵ ۵Ű ϰ ȴ.

漼 ȭ ù° ܰ CCAAT enhancer–binding proteins C/EBP & , glucocorticoid receptor(GR), signal transducer & activator of transcription 5A(STAT5A), cAMP-response element-binding protein(CREB) ڱ Ǹ ̵鿡 Ȱȭ ٸ ڵ PPAR2 C/EBP ι° ܰ踦 漼 α׷(adipocyte gene programing) ϰ ȴ. ̷ ü chromatin ̵ ڵ ټ(chromatin ) 䱸Ǵµ 漼 ʱ ܰ迡 Ͻ Ͼ ְ 漼 ϰ ȴ. ׷ C/EBP ù° ܰ迡 chromatin ۿϴ ˷ ִ.

׷ ᱹ 漼 ο ¿ȴٰ Ѵ. ׸ ̶ ٽ PPAR㰡 ϰ ȴ. 漼 ο 4ܰ , uptake of metabolic substrate( ), lipogenesis( ), lipolysis (), lipid export ( ) ְ ܰ迡 PPAR㰡 ϰ ִ.

漼 ̿Ǵ 1 metabolic substrates() glucose, triacylglycerol(TAG), long chain fatty acids(LCFAs) شǸ, 漼 LCFA ٽ TAG ȯ perilipin ȭ ü ϰ Ǹ鼭 ñ (lipogenesis) Ͱȴ. ݸ (lipolysis) ִ (TAG) θ ȣϰ ִ perilipin иϿ lipase ۿ ְ ϴ ʿϸ ̷ ҾTAG cytosolic lipase diacylglycerol Ǵ monoacylglycerol صȴ ̷ ظ LCFA (lipid export) Ȯϰ ˷ յ flipper protein ִ δٰ Ѵ. ó 漼substrate uptake lipogenesis , lipolysis lipid export ҿ ¿ǹǷ ߿ϴ.

׷ PPAR̴, PPAR , , , ݱ, ַ Ǹ eicosanoidfree fatty acid ȰȭǴµ, ٷ fibrate ๰ ̿ ۿϿ HDL TG ҽ 󵿸ȯ ġ ȴ. ȭ ʿ ڵ ̿ ִ. PPAR, 淮 ҿ ȭ ϴ ڷμ Ѵ. PPAR ȭ ϴ ܹ ۿ ܵ帮Ƴ UCP(¦Ǯ ܹ) ߻, Ҹ ϴ ڵ 縦 ϴ ̵ ۿ ½Ű ġ Ÿ ִ.

ٽ, PPAR ռ ó 漼(adipogenesis) ȭ Ĺݺο Ÿ 漼üܰ迡 ϴ Ȱȭ Ǹ 翡 õ پ ڵ ϱ Ѵ. 漼 lipoprotein lipase (LPL) к TG(triglyceride) LCFA(long chain fatty acid) CD36 FATP1(fatty acid transfer protein 1) Ʈ͸ ̵ LCFA 漼 ´.

漼 aP2 ˷ FABP4 Ÿµ ̴ LCFA ģȭ 漼 κ LCFA ̿ յǾ ϰ ִ. ̷ LCFA TG ȯ perilipin ü ̷ ȴ. Perilipin TG ü ִ · ϸ鼭 ȭ۵ ⿩ PKA(protein kinase A) λȭ Ǵ ̻ ȣ ϰ (lipolysis) Ͼ ȴ.

˷ ִٽ PPAR glucose metabolism ڵ鿡 õ ִ. Ư Phosphoenolpyruvate carboxy kinase (PEPCK) 漼 pyruvate glycerol-3-phosphate (G3P) ȯ ϱ⿡ 漼 TG(triglyceride) 忡 ־ ٽ Ѵ Pyruvate dehydrogenase (PDH) ݴ pyruvate acetyl-co A ϴµ ֿ ȭ , 漼 ٸ ȿ pyruvate dehydrogenase kinase 4 (PDK4) ̷ PDH Ȱ Ͽ TG ϰ ȴ. ̷ PEPCK Բ, ȭ(acetyl-coA) G3Pռ pyruvate ٲ ´. Ż(gluconeogenic pathway) G3P ռ 漼 glycerol 3 kinase ̵ ְ glycerol G3Pռ ⿡ ߿ϴ. PPAR (glycolysis) glucokinase (GK) 6- phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3)͵ õ ִ.

ϸ Ȱȭ PPAR substrate uptake LPL, CD36, FATP1, lipogenesis FABP4, PEPCK, GK, PFKFB3, Perilipin, ׸ PDH ϴ PDK4 ̵ 漼 漼ü ȭӸ ƴ϶ ȣ ߿ ϴ ̴. 漼 PPAR ռ ϰ ǰ е (glycolysis) ռ ϰ ȴ. , ̿ ׸ 漼 ɼ 漼 ̴. Ƽ(thiazolidine) üPioglitazone PPAR 㸦 ڱؼ ν 索 ü ۿ ִ ȴ.

׷ ̷ 漼 Ư¡ PPAR㸸 ƴϴ. ׷ٸ ̿ Ȳ ڵ鿡 Ŀ ϱ ϱ?
ϸ (dailypharm@dailypharm.com) ٸ
  • μ
  • īī
  • ̽
  • Ʈ
  • 0
ǰ
0
͸ǰ | Ǹǰ߾ Ģ
ݱ

Ǹ ͸ , Ǹ ̸ ̵ ˴ϴ. ͸ ʸ ϸ, ͸ մϴ.

ڹ(-ڴϾ-ʱ ) ˵ ϸ ȸ Խ ⡯ ĺ Ʈ ׻ ֻܿ ˴ϴ. ο ø Ϲȸ Խ ĺ ڴϾ ȸ ϴܿ ǽð ˴ϴ.

뺸 ϰ ̵ ̿ Ǵ ֽϴ.

  • ۱ǡΰݱ Ÿ Ǹ ħϴ

    α׷ ϰ , ȳϴ Խù

    Ÿ Ǵ 3 ۱ Ÿ Ǹ ħ Խù

  • ٰ 桤 Ѽϴ Խù

    Ư ̿ ο ν 弳

    Ư 븳 ϴ

    Ȯ ȵ ҹ Ű

    弳 , Ӿ

    Ź, ɿ ˵Ǵ ( û )

    Ư ̳ ü ϴ

    Ư ѼϿ ش ûϴ

    Ư (ֹεϹȣ, ȭ, ּ ) Խϴ

    Ÿ ID Ȥ г ϴ

  • Խ Ư ѵǴ

    ʴ

    翡 ߺ

    κ Ͽ ݺ ϴ 쵵

    Խù,

    Ե Խù

    Խù б

  • û ִ

  • Ÿ

    ʿ伺 ̸

    Ÿ ˵Ǵ 縦

    Ÿ  ڰ ʿϴٰ ǴܵǴ

  • Ȯ

    ۱ڷκ , , ϴ

    Ÿ ʻ ħϰų ϴ

    翡 ̿ (Ÿ ID, йȣ )

  • ̻ Ϻ ׿ ̿ 縦 , Ρ ó ֽϴ.

    õ ̴ ҹ Ǵܵǰų ϸ 񽺿 ٶ ʴٰ ǴܵǴ ġ ϰڽϴ.

    رŸ ϸ ڿ ֽʽÿ. ּҴ dailypharm@dailypharm.comԴϴ.

ֽż ݴ
ٺ Ϲݾ ǸŰ (2023 06)
౹ 66
ǰ ְ
ڶ(20) 6,500 5,500 1,000 6,214
ѽŻ÷(10) 3,500 2,000 1,500 2,940
޾(100) 25,000 22,000 3,000 23,667
Ʒγΰ(100) 30,000 24,000 6,000 27,773
īɾ(10g) 7,000 5,500 1,500 6,381
Ľõ򿬰(5g) 5,000 3,800 1,200 4,537
Ź(4) 5,000 3,500 1,500 4,314
λ絹÷(100) 37,000 28,900 8,100 31,442
̰źĸ(100) 36,000 30,000 6,000 32,844
(10) 6,000 4,000 2,000 4,848
Ժ(10) 4,000 3,000 1,000 3,373
ڱ׸(20) 5,000 3,500 1,500 4,178
ť(10) 3,000 2,000 1,000 2,761
Ȱť(1) 1,200 800 400 972
Ǯɾ(3.3ml) 25,000 22,000 3,000 23,571
޵𿬰(10g) 7,000 5,000 2,000 6,050
öŸ(34) 13,000 9,800 3,200 11,668
뽺ī(20g) 20,000 18,000 2,000 19,607
ġ(1) 1,000 1,000 0 1,000
ӽ÷(21) 10,000 7,500 2,500 8,861
ͺ(10) 3,500 2,200 1,300 3,011
ݿ(1ڽ) 3,000 2,000 1,000 2,835
׶÷糪ƮŸ(6) 8,000 7,000 1,000 7,563
߽Ÿ(120) 70,000 40,000 30,000 53,462
Źĸ(10ĸ) 3,000 2,000 1,000 2,913
Ÿ̾(120) 60,000 40,000 20,000 48,910
տ(60ĸ) 30,000 25,000 5,000 27,925
Ÿ̷ER(6) 3,000 2,500 500 2,530
ٿ(30g) 12,000 8,000 4,000 10,796
(120) 25,000 18,000 7,000 22,063
Ʒ(6) 4,000 3,000 1,000 3,467
ǽõĸ(270ĸ) 110,000 85,000 25,000 0
B(120) 80,000 60,000 20,000 67,059
׳(10) 3,000 2,000 1,000 2,586
6̺(10) 3,000 2,000 1,000 2,920
(60) 250,000 200,000 50,000 215,000
Ⱦ 12,000 9,000 3,000 10,818
ü



ͳݽŹϹȣ: 00048 | 2005.09.09 | : | : ȣ | ּ: ı 128 SK V1 GL ƮνƼ A 401ȣ
ȭ : 02-3473-0833 |ѽ : 02-3474-0169 | ûҳ⺸ȣå(å ű)
Contact dailypharm@dailypharm.com for more information
ϸ () ϴ ۱ǹ ˵Ǹ, 縦 ֽϴ.